Samlyn Capital
CRVS icon

Samlyn Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Samlyn Capital’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,065,935
Closed -$12.9M – 84
2025
Q1 		$12.9M Sell
4,065,935
-2,601,170
-39% -$12.3M 0.19% 73
2024
Q4 		$35.7M Buy
6,667,105
+2,136,772
+47% +$16M 0.54% 59
2024
Q3 		$23.9M Sell
4,530,333
-1,592,688
-26% -$5.72M 0.36% 71
2024
Q2 		$11.1M Buy
6,123,021
+3,774,658
+161% +$7.03M 0.19% 85
2024
Q1 		$4.18M Sell
2,348,363
-147,896
-6% -$309K 0.07% 91
2023
Q4 		$4.39M Buy
2,496,259
+90,495
+4% +$132K 0.09% 74
2023
Q3 		$3.51M Buy
2,405,764
+299,834
+14% +$634K 0.06% 93
2023
Q2 		$4.82M Buy
+2,105,930
New +$4.38M 0.08% 80

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samlyn Capital's CRVS Position: Q2 2025 in Review

Samlyn Capital sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 4,065,935 shares — an estimated $12.9M sold.

Samlyn Capital first reported a position in CRVS in Q2 2023 and held it in 8 quarters. The position peaked at $35.7M in Q4 2024. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • Samlyn Capital reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Samlyn Capital sold 4,065,935 Corvus Pharmaceuticals shares in Q2 2025, an estimated $12.9M.
  • Samlyn Capital first reported a position in Corvus Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Samlyn Capital's Corvus Pharmaceuticals position peaked at $35.7M in Q4 2024.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on Samlyn Capital's 13F filing for Q2 2025, filed 14 Aug 2025.